2023 Volume 38 Issue 2 Pages 127-132
For chemotherapy in the Clinical Practice Guidelines for Pancreatic Cancer 2022, as in the 2019 edition, first-line chemotherapy for patients with locally advanced, unresectable pancreatic cancer (LC1), second-line chemotherapy for patients with unresectable pancreatic cancer [LC2 (MC2)], and first-line chemotherapy for patients with distant metastases from pancreatic cancer (MC1) were established as Clinical Questions (CQ). The duration of treatment with chemotherapy for patients with unresectable pancreatic cancer, which had previously been designated as a CQ, was moved to the general consensus section, and a new CQ [LC3 (MC3)] was established for first-line chemotherapy for elderly patients. A new CQ (BA1) was established for preoperative adjuvant therapy for patients with borderline resectable pancreatic cancer. For each CQ, another systematic review was conducted and meta-analyses performed as necessary to determine recommendations.
